Tonix Pharmaceuticals Initiates Phase 2 OASIS Trial for Acute Stress Reaction
May 21, 2025 — Tonix Pharmaceuticals announces the initiation of the Phase 2 OASIS trial to evaluate TNX-102 SL for reducing acute stress reaction severity. CEO Dr. Seth Lederman emphasizes the urgent need for treatments following traumatic events in civilian and military populations.